Current Report Filing (8-k)
January 27 2015 - 4:35PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 23, 2015
Mast Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
|
001-32157 |
|
84-1318182 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
|
|
3611 Valley Centre Drive, Suite 500,
San Diego, California |
|
92130 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrants telephone number, including area code: (858) 552-0866
12390 El Camino Real, Suite 150, San Diego, California 92130
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of
the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
On January 23, 2015, Patrick L. Keran, the President, Chief Operating Officer and
Secretary of Mast Therapeutics, Inc. (the Company), began a transition period whereby he will be stepping down from that role and leaving the Company effective February 28, 2015.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
Mast Therapeutics, Inc. |
|
|
|
January 27, 2015 |
|
By: |
|
/s/ Brandi L. Roberts |
|
|
|
|
Name: |
|
Brandi L. Roberts |
|
|
|
|
Title: |
|
Chief Financial Officer and Senior Vice President |
Savara Inc. (AMEX:MSTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Savara Inc. (AMEX:MSTX)
Historical Stock Chart
From Sep 2023 to Sep 2024